- Home
- DERM vs ACTU Comparison
DERM vs ACTU Comparison
Compare DERM & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- ACTU
- Stock Information
- Founded
- DERM 2014
- ACTU 2015
- Country
- DERM United States
- ACTU United States
- Employees
- DERM N/A
- ACTU N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- ACTU
- Sector
- DERM Health Care
- ACTU
- Exchange
- DERM Nasdaq
- ACTU NYSE
- Market Cap
- DERM 140.0M
- ACTU 135.0M
- IPO Year
- DERM 2021
- ACTU 2024
- Fundamental
- Price
- DERM $6.25
- ACTU $8.00
- Analyst Decision
- DERM Strong Buy
- ACTU Strong Buy
- Analyst Count
- DERM 2
- ACTU 1
- Target Price
- DERM $10.00
- ACTU $20.00
- AVG Volume (30 Days)
- DERM 103.6K
- ACTU 42.0K
- Earning Date
- DERM 05-12-2025
- ACTU 05-21-2025
- Dividend Yield
- DERM N/A
- ACTU N/A
- EPS Growth
- DERM N/A
- ACTU N/A
- EPS
- DERM N/A
- ACTU N/A
- Revenue
- DERM $56,134,000.00
- ACTU N/A
- Revenue This Year
- DERM $29.83
- ACTU N/A
- Revenue Next Year
- DERM $54.88
- ACTU N/A
- P/E Ratio
- DERM N/A
- ACTU N/A
- Revenue Growth
- DERM N/A
- ACTU N/A
- 52 Week Low
- DERM $3.20
- ACTU $5.51
- 52 Week High
- DERM $7.29
- ACTU $11.73
- Technical
- Relative Strength Index (RSI)
- DERM 53.65
- ACTU N/A
- Support Level
- DERM $5.98
- ACTU N/A
- Resistance Level
- DERM $6.40
- ACTU N/A
- Average True Range (ATR)
- DERM 0.62
- ACTU 0.00
- MACD
- DERM -0.06
- ACTU 0.00
- Stochastic Oscillator
- DERM 36.97
- ACTU 0.00
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.